Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
0
Authors
Edward Romond
Edward Romond•Daniel Visscher•Norman Wolmark
Published
October 20, 2005
Abstract
We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer.
